Top Purchase Related
Home
>
Node
>
Subnode

Treatment of cancer of the prostate

Vernet, S.G.

Annales d'Urologie 4(1): 9-16

1970

ISSN/ISBN: 0003-4401
PMID: 4194186
Document Number: 27556

Document emailed within 1 workday
Secure & encrypted payments

Fourcade, R-Olivier.; Richaud, P.; Coloby, P.; Malavaud, B. 2007: Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(4 Suppl. 1): 891-910
Horiguchi, A.; Hatakeyama, N.; Ikeuchi, K. 1999: Dynamics of prostate-specific antigen as prognostic factors in endocrine treatment for prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 45(1): 31-35
Habib, F.K.; Ross, M.; Bayne, C.W. 1999: Factors controlling the expression of 5alpha-reductase in human prostate: A possible new approach for the treatment of prostate cancer European Urology 35(5-6): 439-442
Stromberg, J.S.; Martinez, A.A.; Horwitz, E.M.; Gustafson, G.S.; Gonzalez, J.A.; Spencer, W.F.; Brabbins, D.S.; Dmuchowski, C.F.; Hollander, J.B.; Vicini, F.A. 1997: Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment Cancer Journal from Scientific American 3(6): 346-352
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Sun, S.-C.; Zhao, H.; Liu, R.; Wang, B.-L.; Liu, Y.-Q.; Zhao, Y.; Shi, Z.-D. 2017: Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells Zhonghua Nan Ke Xue 23(2): 120-124
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Grosclaude, P.; Menegoz, F.; Schaffer, P.; Macé Lesec'h, J.; Arveux, P.; Le Mab, G.; Soulié, M.; Villers, A. 1997: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990 Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(4): 647-654
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Liu, J-he.; Li, H-wei.; Tong, M.; Li, M.; Na, Y-qun. 2004: Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84(5): 364-368
Perrin, P.; François, O.; Maquet, J.H.; Bringeon, G.; Duteil, P.; Devonec, M. 1991: Circulating prostate cancer specific antigens in benign hypertrophy and localized cancer of the prostate Presse Medicale 20(28): 1313-1319
Teodorovich, O.V.; Shatokhin, M.N.; Naryshkin, S.A.; Abdullayev, M.I.; Krasnov, A.V.; Borisenko, G.G.; Zhurbenko, A.A. 2019: Focal laser coagulation in the treatment of a patient with kidney cancer and prostate cancer Urologiia 2: 55-58
Liu, B.-q.; Wu, Y.-d.; Wei, J.-x.; Zhang, T.; Liu, R.-l.; Ma, T.-x. 2007: Expression of prostate cancer antigen-1 in prostate cancer and its clinical significance Zhonghua Nan Ke Xue 13(11): 997-1001
Rébillard, X.; Davin, J-Louis.; Soulié, M. 2003: Treatment by HIFU of prostate cancer: survey of literature and treatment indications Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 13(6): 1428-1456
Fuchsjäger, M.; Akin, O.; Shukla-Dave, A.; Pucar, D.; Hricak, H. 2009: The role of MRI and MRSI in diagnosis, treatment selection, and post-treatment follow-up for prostate cancer Clinical Advances in Hematology and Oncology: H&o 7(3): 193-202
Boccardo, F.; Pace, M. 1993: Endocrine treatment of prostate cancer: standard treatment and new perspectives In Vivo 7(5): 423-424
Eiken, P.A.; Langdahl, B.L.; Eiken, F.L.; Walter, S.; Poulsen, M.Hvid.; Abrahamsen, B. 2011: Prevention and treatment of osteoporosis during treatment of non-metastatic prostate cancer Ugeskrift for Laeger 173(48): 3093-3096
Jager, P.L.; Mensink, H.J.; van den Bergh, A.C.; Piers, D.A. 1999: A strontium-89 injection: a simple treatment of painful bone metastases in patients with prostate cancer unresponsive to hormonal treatment Nederlands Tijdschrift Voor Geneeskunde 143(19): 969-973
Lassen, P.M.; Thompson, I.M. 1994: Treatment options for prostate cancer Urologic Nursing 14(1): 12-15